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An introduction to cl inics and pathophysiology of Myasthenia Gravis (MG) is given in
Chapter I .  The varying involvement of individual muscles, the role of antibodies to the
acetylchol ine receptor (a-AChR) and possible mechanisms for the induction of MG are
discussed. An outl ine of the study is given.
Reviewing the l i terature (Chapter I Ia) i t  can be learned that thymectomy (TE) is general ly
considered as an effect ive therapy in Myasthenia Gravis (MG) but that opinions about
indications for TE are quite divergent. The way of assessing the effect-rate of TE deserves
cri t ical notes in some of the studies on this subject. The duration of MG before TE, the
presence of a thymoma and the way of operation seem to be important factors of inf luence on
the effect of the operation. No improvement of MG after incomplete removal of a thymus
and good results after rethymectomy plea for performance of TE by surgeons with ample
experience of this operations. The r isk of postoperative MG-related complications are a
further argument for concentrat ion of TE to special ized centres. The period between the
operation and cl inical effect of TE varies from patient to patient; most patients do not
improve within the f irst six months after TE. General recommendations concerning periope-
rat ive management are summarized in this chapter.
Our own experience with 100 patients is described in chapter I Ib. No relat ions between
patient factors and the effect of TE were found, except for the fact that severely diseased
patients derived less benefi t  from the operation, as was found by others, and that patients
with thymoma derived considerably less benefi t  from TE. A latent period between operation
and start of improvement was also found in our own group. Because the cl inical course in
those patients benefi t t ing from TE was very stable and general ly no further improvement was
seen three years after the operation we defined benefi t  by TE as improvement of at least two
points on a disabi l i ty scale or complete remission after three years without the inf luence of
immunosuppressive drugs and this definit ion was used in the rest of the study. Our periopera-
t ive protocol is described in I Ib.
Arguments exist for a possible relat ion between HLA-phenotype of the patient and effect of
TE. We studied this relat ion in a group of 20 responders and 20 non-responders (chapter I Ic)
but found the patient 's HLA-type not to be indicative for the effect of TE in MG.
Clinical course and changes in serum levels of antibodies to the acetylchol ine receptor
(a-AChR) were reported in 82 patients with myasthenia gravis during a period of l-8 years
a f te r  TE in  chapter  I I Ia .  Decrease in  a -AChR immedia te ly  a f te r  TE was in f luenced by
changes in total IgG. Immunosuppressive medication lowered serum a-AChR at al l  t ime
points. In a subgroup of 4I patients without thymoma who had no immunosuppressive drugs
there was a steady decrease in a-AChR concomitant with cl inical improvement from 6 weeks
after TE and afterward.
a-AChR serum levels are part ly a result of antibody production by peripheral blood lympho-
cytes (PBL). Spontaneous (SSA) and PWI\4-st imulated (PSA) in vitro production of a-AChR
by PBL were measured in 79 patients with general ized MG as described in chapter I I Ib. SSA
was only found in non-thymomatous early onset MG, and correlated with a poor cl inical
response to TE (TE). PSA was found in patients who had not yet been thymectomized or who
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had derived no benefit from TE. Furthermore, the use of immunosuppressive medication did
not affect PSA. We suggested that measuring PSA after TE might be helpful in the decision
for rethymectomy.
Sixteen patients were fol lowed before and soon after TE in chapter I I Ic. PSA disappeared in
all patients, at least temporarily, between 6 weeks and I year afterwards, independent of the
clinical course and eventual clinical effect of the operation. A recurrence was found only in
one of the f ive patients who derived no benefi t  from the operation.
There was no correlation between the changes in PSA and serum levels of a-AChR suggesting
a minor role of circulat ing PBL and the thymus in the total production of a-AChR.
The findings from chapter IIIb and IIIc support the hypothesis that the therapeutic effect of
TE can be explained by a removal of a source of autoreactive lymphocytes.
The predict ive value of a moderate improvement and antibody-changes at several t ime points
after TE were analyzed in chapter IIId. Both parameters had a considerably predictive value
for the eventual effect of TE: a combination of both parameters was most useful in case of an
unfavourable clinical course.
The role of anti muscle antibodies (AMA) in the diagnosis of a thymoma in patients with
Myasthenia Gravis (MG) is evaluated in chapter IVa. A comparison was made between an
ELISA and Western Blot assay for antibodies to citr ic acid muscle extract (a-CAE) and an
immunofluorescence assay (IF). Sera from 234 selected MG-patients and 123 controls were
tested. There was no essential difference between the ELISA and IF. The Western Blot was
superior in early onset patients but less useful in patients with an onset beyond the age of 40
years. Unusually high post-test probabil i t ies were found by our cri ter ia of patient select ion
which seem most realistic for clinical practice. The Western Blot revealed no differences in
specif ici ty of AMA in thymoma and non-thymoma patients irrespective of age at onset of
disease.
Chapter IVb describes the frequency of anti-skeletal muscle antibodies in non-thymoma
patients. Their occurrence was related to the age at onset in patients with an onset of MG
beyond 40 years and with duration of disease in patients with an earl ier onset of MG. This
stresses the heterogeneity of late onset and early onset MG. Serial measurements in individual
patients revealed no evidence for a direct thymic role in the generation of AMA. There was
no dif ference in specif ici ty of AMA in early and late onset patients. The presence of AMA in
CT-negative patients is not necessari ly suggestive for a radiological shortcoming in the
detection of a thymoma as in 16 AMA posit ive patients from our series no thymoma was
found at operation or autopsy.
Fluctuations of AMA were studied in relat ion to cl inical changes and f luctuations in a-AChR
in chapter IVc. Forty-two patients with general ized myasthenia gravis were studied in cl inical
and serological follow-ups over several years under various conditions. Results from this
study demonstrate that AMA f luctuate in strong relat ion to a-AChR, cl inical course and
immunosuppressive therapy. Thymomectomy resulted in an increase or f i rst appearance of
AMA in ten of the twelve patients without immunosuppressive medication. a-CAE decreased
faster than a-AChR after inst i tut ion of immunosuppressive agents result ing in ct inical
improvement. Further discordances between a-CAE and a-AChR were rarely found and they
did not yield any further information about subsequent cl inical course.
A short synopsis of thymic physiology and pathophysiology in MG is given in chapter Va.
Much evidence for a role of the thymus in the development of self-tolerance has been found
in recent studies. Self-antigens present in the thymus may play a role in this process.
Notwithstanding the presence of myoid cel ls with acetylchol ine-receptors (AChR) in the
normal and also in the MG-th),mus, an autoimmune reaction against the peripheral AChR
occurs in MG. Much 'peripheral '  lymphoid t issue - responding to self-antigen in the thymic
medulla ? - is found in the perivascular spaces of the MG-thymus. The basement membrane
separating the thymic parenchyma from the perivascular space is found disrupted in MG and
an abnormal high proport ion of B-lymphocytes is found the medulla. In vitro studies showed
that the t l ' rymus provides a favourable mil ieu for dif ferentiat ion of B lymphocytes and that
a-AChR can be produced in a high rate by thymic B-lymphocytes. Proteins with AChR-l ike
features are present in thymic tumors and may induce a cross-reaction against peripheral
AChR.
In Chapter Vb, histological f indings in our own group of 53 non-thymoma patients are
described. The resemblance of thymic fol l ic les with peripheral lymph node fol l ic les was
confirmed. Diffuse B-cel l  inf i i t rat ion (thymit is) in the medulla was found in al l  thymuses of
our series (also in the preparates in which no fol l ic les were found with HE-staining). A high
proport ion of IgA+ B-lymphocytes and plasma cel ls was found in MG-thymuses and in
addit ion some MG-thymuses contained large numbers of CD57+ cel ls. We found no dif feren-
ces in thymic histology between responders and non-responders to TE. No relat ion between
thymic histology and a-AChR antibody levels was found. Like others, we did f ind a tendency
that severe hyperplasia was related to a greater delay of improvement.
The main conclusions of this study are summarized in chapter VI. Cl inical implications are
discussed. Some hypotheses about the role of the thymus in MG and possible mechanisms of
TE as therapy for MG are reviewed.
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